获取演示
Now livetag icon
The official Gen AI Landscape report for 2026 is here. Don’t miss out!Get your copybanner icon
Vera Therapeutics

七月 2026

  • Home
  • Vera Therapeutics

七月 2026的Vera Therapeutics市场份额分析

Vera Therapeutics Executive Leadership Team and Board of Directors provide strategic guidance informed by deep expertise in scientific, clinical, operational, and financial experience.
成立年份2016
员工201 - 500
年营收--
veratx.com
Vera Therapeutics
Vera Therapeutics(包含公司地区分支机构)
  • veratx.com
    veratx.com
查看更多网站流量和参与度信息

Vera Therapeutics热门域名的总访问量

了解Vera Therapeutics市场份额和潜在市场覆盖范围。

过去 3 个月的总访问量

子公司明细

Vera Therapeutics热门域名的平均访问时长

分析Vera Therapeutics参与度指标。

过去 3 个月的平均访问时长

子公司明细

Vera Therapeutics热门域名的平均页面浏览量

了解Vera Therapeutics如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。

过去 3 个月的平均页面浏览量

子公司明细

想要获取更深入的流量洞见?

过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。



Vera Therapeutics 采用的主要技术

这些是排名前 Vera Therapeutics 的顶级域名所使用的网站技术(按行业分列)

付款和货币 (8)

Cart Functionality

Cart Functionality

付费广告 (5)

DoubleClick

DoubleClick

小部件 (4)

转化和分析 (3)

Google Analytics

Google Analytics

更多技术

13

查看全部

准备好发现优质潜在客户了吗?

借助 Similarweb 销售情报解决方案,确定任意网站使用了哪些技术来设计完美的销售宣传,并缩短销售周期。


Vera Therapeutics 的新闻与信号

借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。

新闻Vera Therapeutics, Inc. identified as competitor of Otsuka Us on Jul 1st '26.Vera Therapeutics has won FDA approval for Trutakna, a BAFF/APRIL inhibitor for IgA nephropathy (IgAN) that will compete with Otsuka's recently approved anti-APRIL drug Voyxact.
新闻Vera Therapeutics, Inc. identified as competitor of Novartis AG on Jul 7th '26.Vera Therapeutics' atacicept, to be marketed as Trutakna, will go up against Novartis, Otsuka and possibly Vertex in the kidney disease primary IgA nephropathy after receiving an accelerated FDA approval.
新闻Vera Therapeutics, Inc. identified as competitor of Vertex Pharmaceuticals on Jul 7th '26.Vera Therapeutics Inc. looks to get an almost five-month head start over a competitor, Vertex Pharmaceuticals Inc., as the U.S. FDA cleared its Trutakna (atacicept) as the first dual BAFF/APRIL inhibitor for treating immunoglobulin A nephropathy (IgAN).

查看 Vera Therapeutics 的所有信号

让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。